Long-range allosteric communication within antibodies affects antigen-binding affinity - Report - MDSpire

Long-range allosteric communication within antibodies affects antigen-binding affinity

  • By

  • Susan K. Vester

  • Brian J. Sutton

  • James M. McDonnell

  • July 3, 2026

  • 0 min

Share

Clinical Report: Allosteric Interactions in Antibodies Influence Antigen-Binding Affinity

Overview

This study investigates the allosteric effects within antibodies on antigen-binding affinities across various isotypes. Significant long-range allosteric interactions were identified, particularly from the Fc region to the Fab region, influencing binding affinities independent of avidity.

Background

Antibodies play a crucial role in the immune response, with different classes exhibiting unique binding properties and effector functions. Understanding the allosteric interactions within antibodies is essential.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Allosteric modulation of antigen binding is influenced by the CH1 domain and Fc region interactions.
  • Full-length antibodies show higher binding affinities compared to Fab fragments, regardless of avidity.
  • Long-range allosteric effects from the Fc region significantly impact antigen-binding affinities.
  • Differences in antibody flexibility and pre-organization drive the observed thermodynamic effects.
  • Small to medium-range allosteric differences were noted among different CH1 domains.

Clinical Implications

The findings provide insights into allosteric interactions in antibodies.

Conclusion

This study provides insights into the allosteric mechanisms that govern antibody function.

Related Resources & Content

  1. the medicine maker, The Medicine Maker, 2026 -- Overcoming the Challenges of AI Antibody Analysis
  2. Archives of Toxicology, Archives of Toxicology, 2016 -- Evaluating the Use of Predictive Toxicology Approaches for Monoclonal Antibody Treatments: Current Status and Future Potential
  3. Frontiers in Immunology, Frontiers in Immunology, 2026 -- Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone
  4. the analytical scientist, The Analytical Scientist, 2026 -- Antibody Oxidation’s Hidden Handedness Comes Into View
  5. Immunogenicity Testing of Therapeutic Protein Products, HHS.gov, 2025 -- Developing and Validating Assays for Anti-Drug Antibody Detection
  6. Overview | Efgartigimod for treating antibody-positive generalised myasthenia gravis | Guidance | NICE, NICE, 2025
  7. A non-classical view of antibody properties: Allosteric effect between variable and constant regions, ScienceDirect, 2024
  8. Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection
  9. Overview | Efgartigimod for treating antibody-positive generalised myasthenia gravis | Guidance | NICE
  10. A non-classical view of antibody properties: Allosteric effect between variable and constant regions - ScienceDirect

Original Source(s)

Related Content